Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure
Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and fa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140276/ https://www.ncbi.nlm.nih.gov/pubmed/21792345 http://dx.doi.org/10.4137/CMC.S4309 |
_version_ | 1782208539902607360 |
---|---|
author | Smart, Neil A. Kwok, Nigel Holland, David J. Jayasighe, Rohan Giallauria, Francesco |
author_facet | Smart, Neil A. Kwok, Nigel Holland, David J. Jayasighe, Rohan Giallauria, Francesco |
author_sort | Smart, Neil A. |
collection | PubMed |
description | Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and failed to show an overall mortality benefit. However, benefits on cardiac mortality and re-hospitalization rates were observed in the BEST trial. Bucindolol has not shown benefits in African Americans, those with significantly low ejection fraction and those in NYHA class IV heart failure. These observations could be due to the exaggerated sympatholytic response to bucindolol in these sub-groups that may be mediated by genetic polymorphisms or changes in gene regulation due to advanced heart failure. This paper provides a timely clinical update on the use of bucindolol in chronic heart failure. |
format | Online Article Text |
id | pubmed-3140276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-31402762011-07-26 Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure Smart, Neil A. Kwok, Nigel Holland, David J. Jayasighe, Rohan Giallauria, Francesco Clin Med Insights Cardiol Review Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with heart failure, was terminated prematurely and failed to show an overall mortality benefit. However, benefits on cardiac mortality and re-hospitalization rates were observed in the BEST trial. Bucindolol has not shown benefits in African Americans, those with significantly low ejection fraction and those in NYHA class IV heart failure. These observations could be due to the exaggerated sympatholytic response to bucindolol in these sub-groups that may be mediated by genetic polymorphisms or changes in gene regulation due to advanced heart failure. This paper provides a timely clinical update on the use of bucindolol in chronic heart failure. Libertas Academica 2011-06-28 /pmc/articles/PMC3140276/ /pubmed/21792345 http://dx.doi.org/10.4137/CMC.S4309 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Review Smart, Neil A. Kwok, Nigel Holland, David J. Jayasighe, Rohan Giallauria, Francesco Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title | Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title_full | Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title_fullStr | Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title_full_unstemmed | Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title_short | Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure |
title_sort | bucindolol: a pharmacogenomic perspective on its use in chronic heart failure |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140276/ https://www.ncbi.nlm.nih.gov/pubmed/21792345 http://dx.doi.org/10.4137/CMC.S4309 |
work_keys_str_mv | AT smartneila bucindololapharmacogenomicperspectiveonitsuseinchronicheartfailure AT kwoknigel bucindololapharmacogenomicperspectiveonitsuseinchronicheartfailure AT hollanddavidj bucindololapharmacogenomicperspectiveonitsuseinchronicheartfailure AT jayasigherohan bucindololapharmacogenomicperspectiveonitsuseinchronicheartfailure AT giallauriafrancesco bucindololapharmacogenomicperspectiveonitsuseinchronicheartfailure |